Author: Customer Service

Brings world class validation, technical scientific research and development expertise to establish Canada’s first deep subsurface Natural Hydrogen program.Strategic technical collaboration with globally recognized PTRC further solidifies MAX Power’s leadership in the pursuit of the world’s first commercial Natural Hydrogen discovery. The MAX Power-PTRC collaboration marks a major milestone in advancing sustainable energy innovation across Saskatchewan through the exploration and potential near-term development of Natural Hydrogen resources in the province.SASKATOON, Saskatchewan, Oct. 10, 2025 (GLOBE NEWSWIRE) — MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) (“MAX Power” or the “Company”), rapidly moving toward the start of drilling on the Genesis Natural Hydrogen Trend in Saskatchewan, is pleased to announce...

New Vision Highlights USBC’s Retail Tokenized Deposit Strategy RENO, Nev., Oct. 10, 2025 (GLOBE NEWSWIRE) — USBC, Inc. (NYSE American: USBC) (“USBC”) today announced its participation at the Money20/20 USA conference, the flagship global event for financial technology and innovation, from October 26-29, 2025, at the Venetian Resort in Las Vegas, Nevada. USBC’s presence at Money20/20 comes at a pivotal time, following its strategic acquisition of a public company this past summer and unveiling of a new vision driven by USBC tokenized deposits. Led by Chairman and CEO Greg Kidd, USBC is positioning tokenized deposits as the centerpiece of a new era in compliant, programmable digital U.S. dollars. Unlike traditional stablecoins, the USBC tokenized deposits are backed by an OCC-chartered U.S. bank and underpinned by blockchain technology,...

-Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile- -The AATD program, CTX460, is the first investigational candidate to emerge from the SyNTase editing platform and the Company expects to initiate a clinical trial with CTX460 in mid-2026- -CTX460 showed specific and durable effects, with >90% mRNA correction, a 5-fold increase in total AAT levels, and >99% serum M-AAT:Z-AAT ratio in AATD disease models– ZUG, Switzerland and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported new preclinical data from its novel SyNTase™ gene editing platform for the treatment of Alpha-1 Antitrypsin Deficiency (AATD)....

NEWTOWN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) — Solana Company, (NASDAQ:HSDT or “the Company”), formerly Helius Medical Technologies, Inc., today announced it has entered into agreements with Coinbase, BitGo and Anchorage Digital to serve as custodians as it continues amassing SOL, the native asset of the Solana Network, as part of its digital assets treasury strategy. “As HSDT continues to operate as the preeminent SOL-focused treasury, establishing relationships with leading custodians like Coinbase, BitGo, and Anchorage Digital reflects our disciplined and scalable approach to maximizing shareholder value,” said Cosmo Jiang, General Partner at Pantera Capital and Board Observer at HSDT. “This custody framework significantly strengthens the foundation for HSDT’s strategy.” “These custodial relationships strengthen HSDT’s...

New York, NY, Oct. 10, 2025 (GLOBE NEWSWIRE) —AlphaTON Capital (NASDAQ: ATON), a specialized digital asset treasury company focused on developing the TON and Telegram ecosystem, and new pioneer in blockchain-based healthcare financing, today announced that Nasdaq has publicly congratulated the company on its innovative approach to funding cancer research through asset tokenization. The recognition was displayed prominently on the iconic Nasdaq Tower in Times Square, marking a significant milestone in the convergence of digital assets and medical research funding. Transforming Cancer Treatment Through Tokenization AlphaTON Capital’s partnership with Cyncado Therapeutics represents a revolutionary approach to financing life-saving cancer research. By leveraging blockchain technology and asset tokenization, the company has...

SAINT-BRUNO-DE-MONTARVILLE, Quebec, Oct. 10, 2025 (GLOBE NEWSWIRE) — Colabor Group Inc. (TSX: GCL) (“Colabor” or the “Company”) will release its results for the third quarter ended September 6, 2025, after market close on Thursday, October 16, 2025. A conference call to discuss these results will be held on Friday, October 17, 2025 at 9:30 a.m. (Eastern Time). Conference Call: A live broadcast of the conference call will be available on the Company’s website, in the Investors section under Events and presentations. To participate (professional investment community only) or to listen to the live conference call:Date: Friday, October 17, 2025Time: 9:30 a.m. (Eastern Time)   Conference Number: 60051North-American participants dial toll-free: 1-800-990-4777International and local dial-in: 1-289-819-1299 or 1-514-400-3794You...

HONG KONG, Oct. 10, 2025 (GLOBE NEWSWIRE) — Reitar Logtech Holdings Limited (NASDAQ:RITR)(“Reitar” or “The Company”), Asia’s leading integrated Property + Logistics Technology (PLT) solutions platform, announced at the “Reitar Global Food Supply Chain Ecological Seminar”, a strategic partnership with China’s top casual catering supply chain provider, Hangzhou Xianmu Technology Co., Ltd. (“Xianmu”). Xianmu delivers one-stop smart supply chain solutions for the casual catering market, covering more than 120 major cities and benefiting over 300,000 restaurant clients. Its founder, Jiang Tao, along with several co-founders, has previously worked at Alibaba, possessing rich experience in supply chain and digital transformation, leading Xianmu to successfully complete multiple rounds of financing and technological innovation. Through...

Presentation title: “Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine”NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Prof. Dr. Timo Grimmer, MD, member of the Anavex Scientific Advisory Board and National Coordinating Investigator for the blarcamesine Phase IIb/III ANAVEX®2-73-AD-004 study gave an oral presentation titled, “Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families...